【摘要】：目的:觀(guān)察膦甲酸鈉聯(lián)合重組人干擾素α2b治療宮頸人乳頭瘤病毒(HPV)持續(xù)感染的臨床療效。方法:選取宮頸HPV持續(xù)感染患者65例,按照隨機(jī)數(shù)字表法分為治療組(n=35)和對(duì)照組(n=30)。兩組患者均給予重組人干擾素α2b栓10萬(wàn)IU,qod(睡前),治療時(shí)間為3個(gè)月;治療組患者在此基礎(chǔ)上給予膦甲酸鈉氯化鈉注射液250 m L,ivgtt,qd,治療時(shí)間為14 d。觀(guān)察兩組患者根據(jù)HPV病毒載量判定的療效、HPV轉(zhuǎn)陰率、宮頸炎評(píng)分、根據(jù)宮頸炎評(píng)分改善率判定的療效及不良反應(yīng)發(fā)生情況。結(jié)果:治療組患者根據(jù)HPV病毒載量判定的總有效率(94.29%)明顯高于對(duì)照組(76.67%),差異有統(tǒng)計(jì)學(xué)意義(P0.05);治療組患者HPV轉(zhuǎn)陰率(77.14%)明顯高于對(duì)照組(36.67%),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者宮頸炎評(píng)分均較治療前明顯降低,且治療組[(1.49±0.70)分]明顯低于對(duì)照組[(1.97±0.89)分],差異均有統(tǒng)計(jì)學(xué)意義(P0.05);治療組患者根據(jù)宮頸炎評(píng)分改善率判定的總有效率(88.57%)明顯高于對(duì)照組(73.33%),差異有統(tǒng)計(jì)學(xué)意義(P0.05)。兩組患者治療過(guò)程中均未見(jiàn)不良反應(yīng)發(fā)生。結(jié)論:膦甲酸鈉聯(lián)合重組人干擾素α2b能有效抑制HPV病毒復(fù)制、提高HPV轉(zhuǎn)陰率、緩解宮頸炎癥狀,且安全性較高。
[Abstract]:Objective: to observe the clinical effect of phosphonium formate combined with recombinant human interferon 偽 2b in the treatment of persistent cervix human papillomavirus (HPV) infection. Methods: 65 patients with persistent cervical HPV infection were randomly divided into treatment group (n = 35) and control group (n = 30). The patients in both groups were treated with recombinant human interferon 偽 2b suppository for 100000 IU,qod (before bedtime) for 3 months, and patients in the treatment group were treated with phosphonium sodium chloride injection 250ml iv gttttqd for 14 days. To observe the curative effect of the two groups according to the viral load of HPV and the negative rate of HPV, the score of cervicitis, the curative effect according to the improvement rate of the score of cervicitis and the occurrence of adverse reactions. Results: the total effective rate (94.29%) of HPV viral load in the treatment group was significantly higher than that in the control group (76.67%), the difference was statistically significant (P0.05), and the negative rate of HPV in the treatment group (77.14%) was significantly higher than that in the control group (36.67%) (P0.05). The score of cervicitis in both groups was significantly lower than that before treatment. The treatment group [(1.49 鹵0.70) score] was significantly lower than the control group [(1.97 鹵0.89) score], the difference was statistically significant (P0.05), the total effective rate of the treatment group according to the cervicitis score improvement rate (88.57%) was significantly higher than that of the control group (73.33%), the difference was statistically significant (P0.05). There were no adverse reactions in both groups. Conclusion: phosphonium formate combined with recombinant human interferon 偽 2b can effectively inhibit the replication of HPV virus, increase the negative rate of HPV, relieve the symptoms of cervicitis, and have high safety.
【作者單位】： 山東大學(xué)第二醫(yī)院婦產(chǎn)科;
【分類(lèi)號(hào)】：R737.33

【相似文獻(xiàn)】

相關(guān)期刊論文 前10條

1 高錦娟,紀(jì)莎;重組人干擾素α-2b致精神癥狀[J];藥物不良反應(yīng)雜志;2003年05期

2 李堅(jiān);趙淑清;徐迎勝;;干擾素α-2b致急性炎癥性脫髓鞘性多發(fā)性神經(jīng)病[J];藥物不良反應(yīng)雜志;2006年02期

3 國(guó)澤延;;干擾素α-1b重復(fù)治療慢性乙型病毒性肝炎26例療效觀(guān)察[J];當(dāng)代醫(yī)學(xué);2012年21期

4 陸堅(jiān),馬為民,王火生;干擾素抗體對(duì)干擾素α-1b療效影響的動(dòng)態(tài)研究[J];臨床肝膽病雜志;2000年04期

5 王椿;干擾素在血液系統(tǒng)惡性腫瘤的治療價(jià)值[J];醫(yī)師進(jìn)修雜志;2000年11期

6 王春生,吳晶;重組干擾素α-2a栓抗Ⅱ型單純皰疹病毒作用[J];中國(guó)醫(yī)院藥學(xué)雜志;2000年03期

7 賈青青,王曉玲;慢性乙型病毒性肝炎患者血清可溶性細(xì)胞間粘附分子-1水平與干擾素療效的關(guān)系[J];河北醫(yī)藥;2000年03期

8 周岳進(jìn);慢性乙型病毒性肝炎干擾素初治失敗后的治療[J];胃腸病學(xué)和肝病學(xué)雜志;2000年02期

9 毛長(zhǎng)庚;干擾素引發(fā)全血象降低1例[J];中華肝臟病雜志;2001年06期

10 陳琦,石小巖;重組人干擾素α經(jīng)鼻腔給藥用于預(yù)防和治療上呼吸道病毒性感染的前景[J];中國(guó)醫(yī)院藥學(xué)雜志;2003年07期

相關(guān)會(huì)議論文 前10條

1 周岳進(jìn);;慢性乙型病毒性肝炎干擾素初治失敗后的治療[A];中國(guó)中西醫(yī)結(jié)合學(xué)會(huì)第十二次全國(guó)消化系統(tǒng)疾病學(xué)術(shù)研討會(huì)論文匯編[C];2000年

2 賈珍容;徐雪元;閔e，

本文編號(hào)：2237605